Gemcitabine + Paclitaxel + Carboplatin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Genital Neoplasms, Female
Conditions
Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms
Trial Timeline
Oct 1, 2002 → Aug 1, 2009
NCT ID
NCT00191646About Gemcitabine + Paclitaxel + Carboplatin
Gemcitabine + Paclitaxel + Carboplatin is a phase 3 stage product being developed by Eli Lilly for Genital Neoplasms, Female. The current trial status is completed. This product is registered under clinical trial identifier NCT00191646. Target conditions include Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00191646 | Phase 3 | Completed |
Competing Products
20 competing products in Genital Neoplasms, Female
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tideglusib | AMO Pharma | Pre-clinical | 15 |
| Tideglusib + Placebo | AMO Pharma | Phase 2/3 | 57 |
| Tideglusib | AMO Pharma | Phase 2/3 | 57 |
| Fulvestrant + Abemaciclib | Eli Lilly | Phase 2 | 52 |
| EDIT-101 | Editas Medicine | Phase 1/2 | 33 |
| Gemcitabine + liposomal doxorubicin | Eli Lilly | Phase 3 | 77 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont | Spruce Biosciences | Phase 2 | 44 |
| ASP2151 + Placebo | Astellas Pharma | Phase 1 | 33 |
| ASP2151 + valacyclovir + Placebo | Astellas Pharma | Phase 2 | 52 |
| Tildrakizumab 100 mg + Placebo | Sun Pharmaceutical | Phase 3 | 77 |
| Topical NO + Placebo | Kyowa Kirin | Phase 2 | 52 |
| KW-3357 | Kyowa Kirin | Phase 1 | 33 |
| Ixekizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Daratumumab | Johnson & Johnson | Phase 2 | 52 |
| Risankizumab + Placebo for Risankizumab | AbbVie | Approved | 85 |
| Ropivacaine + Epinephrine + Decadron + Clonidine + Propofol | Merck | Phase 3 | 77 |